X4 PHARMACEUTICALS, INC (XFOR) Spending and interest coverage
- R&D / revenue · 12 months: Value 418.92%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 53.83%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 418.92% | Research and development expense / revenue. Period ending 2026-06-30. $66.39M ÷ $15.85M × 100 ≈ 418.92% |
| Stock-based compensation / revenue · 12 months | 53.83% | Share-based compensation / revenue. Period ending 2026-06-30. $8.53M ÷ $15.85M × 100 ≈ 53.83% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 66.39M USD | Research and Development Expense |
| Revenue | 15.85M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 8.53M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -87.91M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $66.39M | $15.85M | $8.53M | $-87.91M | (m) | 418.92% | 53.83% | (m) | (m) |
| 2026-03-31 | $69.66M | $9.01M | $6.19M | $-97.75M | (m) | 772.80% | 68.69% | (m) | (m) |
| 2025-12-31 | $72.72M | $35.11M | $4.30M | $-86.88M | (m) | 207.11% | 12.24% | (m) | (m) |
| 2025-09-30 | $75.90M | $33.98M | $4.24M | $-98.90M | (m) | 223.39% | 12.49% | (m) | (m) |
| 2025-06-30 | $77.74M | $32.77M | $5.30M | $-105.89M | (m) | 237.20% | 16.18% | (m) | (m) |
| 2025-03-31 | $80.30M | $31.36M | $6.98M | $-8.55M | (m) | 256.03% | 22.27% | (m) | (m) |
| 2024-12-31 | $81.64M | $2.56M | $8.20M | $-36.40M | (m) | 3192.92% | 320.84% | (m) | (m) |
| 2024-09-30 | $75.21M | (m) | $8.53M | $-25.89M | $8.35M | (m) | (m) | -3.10× | Reported |
| 2024-06-30 | $75.12M | (m) | $9.07M | $-18.60M | $7.57M | (m) | (m) | -2.46× | Reported |
| 2024-03-31 | $69.81M | (m) | $8.78M | $-115.51M | $6.54M | (m) | (m) | -17.66× | Reported |
| 2023-12-31 | $72.02M | (m) | $8.69M | $-107.52M | $5.78M | (m) | (m) | -18.61× | Reported |
| 2023-09-30 | $75.76M | (m) | $7.25M | $-107.90M | $5.04M | (m) | (m) | -21.43× | Reported |
| 2023-06-30 | $70.79M | (m) | $6.00M | $-100.84M | $4.42M | (m) | (m) | -22.82× | Reported |
| 2023-03-31 | $69.01M | (m) | $5.38M | $-95.61M | $4.19M | (m) | (m) | -22.82× | Reported |
| 2022-12-31 | $61.06M | $0.00 | $5.20M | $-87.57M | $3.99M | (m) | (m) | -21.93× | Reported |
| 2022-09-30 | $54.21M | (m) | $5.70M | $-91.05M | $3.77M | (m) | (m) | -24.12× | Reported |
| 2022-06-30 | $53.28M | (m) | $6.11M | $-90.01M | $3.68M | (m) | (m) | -24.49× | Reported |
| 2022-03-31 | $52.66M | (m) | $6.38M | $-88.44M | $3.66M | (m) | (m) | -24.14× | Reported |
| 2021-12-31 | $50.65M | $0.00 | $6.18M | $-85.11M | $3.64M | (m) | (m) | -23.37× | Reported |
| 2021-09-30 | $50.78M | $0.00 | $5.97M | $-73.71M | $3.44M | (m) | (m) | -21.45× | Reported |
| 2021-06-30 | $48.98M | $0.00 | $6.70M | $-71.57M | $3.21M | (m) | (m) | -22.27× | Reported |
| 2021-03-31 | $45.13M | $0.00 | $6.07M | $-67.23M | $3.00M | (m) | (m) | -22.45× | Reported |
| 2020-12-31 | $41.93M | $3.00M | $5.43M | $-59.87M | $2.69M | 1397.73% | 180.93% | -22.27× | Reported |
| 2020-09-30 | $36.70M | (m) | $4.69M | $-53.09M | $2.52M | (m) | (m) | -21.10× | Reported |
| 2020-06-30 | $33.91M | (m) | $3.14M | $-53.09M | $2.51M | (m) | (m) | -21.18× | Reported |
| 2020-03-31 | $33.42M | (m) | $2.40M | $-51.85M | $2.33M | (m) | (m) | -22.23× | Reported |
| 2019-12-31 | $30.16M | (m) | $2.05M | $-51.70M | $2.15M | (m) | (m) | -24.08× | Reported |
| 2019-09-30 | $38.42M | (m) | $6.54M | $-65.68M | $2.15M | (m) | (m) | -30.49× | Reported |
| 2019-06-30 | $35.99M | (m) | $6.04M | $-57.25M | $1.61M | (m) | (m) | -35.47× | Reported |
| 2019-03-31 | $31.89M | (m) | $5.75M | $-50.21M | $1.27M | (m) | (m) | -39.57× | Reported |
| 2018-12-31 | $30.98M | $3.50M | $5.62M | $-45.88M | $1.04M | 885.11% | 160.57% | -44.16× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $28.13M | (m) | $906.00K | $-36.13M | $2.08M | (m) | (m) | -17.38× | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $17.83M | (m) | $644.00K | $-24.35M | $2.52M | (m) | (m) | -9.68× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |